Aktienanalyse zu BioCryst Pharmaceuticals, Inc. (BCRX)BCRXBioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

BioCryst Pharmaceuticals Inc (BCRX) is currently trading at $7.79, which is below the average analyst price target of $12 to $13, indicating potential upside. However, the stock has a low RSI of 27.65, suggesting it is oversold, but recent performance shows a 5-day decline of 8.89%, reflecting negative sentiment. The main risk is the downgrade by RBC, which has lowered its price target to $11 due to competitive pressures affecting revenue from Orladeyo, which is projected to drop to $400 million to $450 million in the long term. Therefore, while there is potential for recovery, the current market conditions and analyst sentiment suggest holding rather than buying at this moment.